Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Evans LA et al. | Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. | 1996 | Pharm. Res. | pmid:8899856 |
Segreti J et al. | In vitro activity of macrolides against intracellular Legionella pneumophila. | 1996 | Diagn. Microbiol. Infect. Dis. | pmid:8902407 |
Gastearena I et al. | Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. | 1995 | J Chemother | pmid:8904095 |
Domingo S et al. | Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. | 1995 | J Chemother | pmid:8904096 |
Wendel TD | 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. | 1996 Nov-Dec | ACP J. Club | pmid:8912627 |
Luke DR et al. | Safety, toleration, and pharmacokinetics of intravenous azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8913468 |
Olsen KM et al. | Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. | 1996 | Antimicrob. Agents Chemother. | pmid:8913469 |
Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
Aoyama T et al. | Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. | 1996 | J. Pediatr. | pmid:8917247 |
O'Doherty B | Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. | 1996 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:8922571 |
Griffith DE et al. | Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. | 1996 | Clin. Infect. Dis. | pmid:8922790 |
Chulig I | [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. | 1996 | Antibiot. Khimioter. | pmid:8929112 |
Kuznetsova SM | ["Sumamed in the treatment of urogenital infections"]. | 1996 | Antibiot. Khimioter. | pmid:8929115 |
Skripkin IuK et al. | [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. | 1996 | Antibiot. Khimioter. | pmid:8929120 |
Vasil'ev MM and Gazarian IIu | [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. | 1996 | Antibiot. Khimioter. | pmid:8929122 |
Meloni G and Meloni T | Azithromycin vs. doxycycline for Mediterranean spotted fever. | 1996 | Pediatr. Infect. Dis. J. | pmid:8933556 |
Jackson MA et al. | Breakthrough sepsis in macrolide-resistant pneumococcal infection. | 1996 | Pediatr. Infect. Dis. J. | pmid:8933560 |
Keysary A et al. | The in-vitro anti-rickettsial activity of macrolides. | 1996 | J. Antimicrob. Chemother. | pmid:8937968 |
Mein J et al. | Donovanosis: sequelae of severe disease and successful azithromycin treatment. | 1996 | Int J STD AIDS | pmid:8940677 |
Hoque S et al. | Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. | 1996 | Nephrol. Dial. Transplant. | pmid:8941608 |
Wiselka MJ et al. | Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. | 1996 | J. Infect. | pmid:8945715 |
Tansey MJ and Moe JB | Severe neutropenia and prophylactic doses of rifabutin. | 1996 | Lancet | pmid:8950911 |
Sefton AM et al. | Azithromycin in the treatment of periodontal disease. Effect on microbial flora. | 1996 | J. Clin. Periodontol. | pmid:8951627 |
Griffith DE et al. | Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. | 1996 | Clin. Infect. Dis. | pmid:8953085 |
Brihmer C et al. | Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. | 1996 | Scand. J. Infect. Dis. | pmid:8953672 |
Van Bambeke F et al. | Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. | 1996 | Eur. J. Pharmacol. | pmid:8957238 |
Montenez JP et al. | Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. | 1996 | Eur. J. Pharmacol. | pmid:8957239 |
Ripa S et al. | A linear model for the pharmacokinetics of azithromycin in healthy volunteers. | 1996 Nov-Dec | Chemotherapy | pmid:8957574 |
Peeling RW and Brunham RC | Chlamydiae as pathogens: new species and new issues. | 1996 Oct-Dec | Emerging Infect. Dis. | pmid:8969247 |
Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
Pilotto A et al. | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971305 |
Andenaes K et al. | Preoperative bacterial colonization and its influence on postoperative wound infections in plastic surgery. | 1996 | J. Hosp. Infect. | pmid:8971618 |
Pozniak A and Nelson MR | Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. | 1996 | Genitourin Med | pmid:8976832 |
Schwartz RA et al. | Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. | 1996 | Br. J. Dermatol. | pmid:8977724 |
Vranes J | Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. | 1996 May-Jun | Chemotherapy | pmid:8983884 |
Ichimiya T et al. | The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. | 1996 May-Jun | Chemotherapy | pmid:8983885 |
Galova K et al. | Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. | 1996 May-Jun | Chemotherapy | pmid:8983893 |
Akita H et al. | [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8986553 |
Nishimura T et al. | [Clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8986554 |
Haruta T and Kobayashi Y | [Therapeutic efficacy of azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8986555 |
Kuroda Y and Ito M | [Therapy with azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8986556 |
Okamoto T and Sekiguchi T | [Clinical studies on azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8986557 |
Toyonaga Y et al. | [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. | 1996 | Jpn J Antibiot | pmid:8988410 |
Okumura A and Kuno K | [Pharmacokinetic and clinical evaluation of azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8988411 |
Kobayashi Y et al. | [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. | 1996 | Jpn J Antibiot | pmid:8988412 |
Furukawa S and Okada T | [A clinical evaluation of azithromycin in the treatment of pediatric infection]. | 1996 | Jpn J Antibiot | pmid:8988413 |
Okada T et al. | [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8988414 |
Ishida Y et al. | [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8988415 |
Ohtsuka Y et al. | [Pharmacokinetic and clinical studies on azithromycin in children]. | 1996 | Jpn J Antibiot | pmid:8988416 |
Tseng AL et al. | Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. | 1997 | Clin. Infect. Dis. | pmid:8994766 |